Evidence map›Paper›PMID 33150829›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2021

High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients.

Tilman Schneider-Hohendorf, Andreas Schulte-Mecklenbeck, Patrick Ostkamp, Claudia Janoschka, Marc Pawlitzki, Felix Luessi, Frauke Zipp, Sven G Meuth, Luisa Klotz, Heinz Wiendl and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Observational
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Tilman Schneider-HohendorfDepartment of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany.ORCID 0000-0002-3717-5176
Andreas Schulte-MecklenbeckDepartment of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany.
Patrick OstkampDepartment of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany.
Claudia JanoschkaDepartment of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany.
Marc PawlitzkiDepartment of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany.
Felix LuessiDepartment of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (rmn), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Frauke ZippDepartment of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (rmn), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Sven G MeuthDepartment of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany.
Luisa KlotzDepartment of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany.
Heinz WiendlDepartment of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany.ORCID 0000-0003-4310-3432
Catharina C GrossDepartment of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany.
Nicholas SchwabDepartment of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany.ORCID 0000-0001-5494-9885
University of Münster · DEJohannes Gutenberg University Mainz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProgressive multifocal leukoencephalopathy (PML) can in rare cases occur in natalizumab-treated patients with high serum anti-JCPyV antibodies, hypothetically due to excessive blockade of immune cell migration.

objectiveImmune cell recruitment to the central nervous system (CNS) was assessed in relapsing-remitting multiple sclerosis (RRMS) patients stratified by low versus high anti-JCPyV antibody titers as indicator for PML risk.

methodsCerebrospinal fluid (CSF) cell counts of 145 RRMS patients were quantified by flow cytometry. Generalized linear models were employed to assess influence of age, sex, disease duration, Expanded Disability Status Scale (EDSS), clinical/radiological activity, current steroid or natalizumab treatment, as well as anti-JCPyV serology on CSF cell subset counts.

resultsWhile clinical/radiological activity was associated with increased CD4, natural killer (NK), B and plasma cell counts, natalizumab therapy reduced all subpopulations except monocytes. With and without natalizumab therapy, patients with high anti-JCPyV serum titers presented with increased CSF T-cell counts compared to patients with low anti-JCPyV serum titers. In contrast, PML patients assessed before (

conclusionHigh anti-JCPyV indices, which could be indicative of increased viral activity, are associated with elevated immune cell recruitment to the CNS. Its excessive impairment in conjunction with viral activity could predispose for PML development.

Indexed as

JC VirusLeukoencephalopathy, Progressive MultifocalMultiple Sclerosis, Relapsing-RemittingCell CountHumansNatalizumabNatalizumabcerebrospinal fluidclinical activityCSF cell countsJCPyVJCV indexMultiple sclerosisnatalizumabprogressive multifocal leukoencephalopathytissue-resident memory cells

Identifiers

PMID33150829
PMCPMC8414828
OpenAlexW3096517284

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.